How should I switch from Lexapro (escitalopram) to Zoloft (sertraline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Lexapro to Zoloft

When switching from Lexapro (escitalopram) to Zoloft (sertraline), you can perform a direct cross-taper without a washout period, starting sertraline at 25-50 mg while gradually tapering escitalopram over 1-2 weeks to minimize discontinuation symptoms. 1, 2

Switching Strategy

Both escitalopram and sertraline are SSRIs with similar mechanisms of action, which allows for a straightforward transition without the mandatory washout period required when switching to/from MAOIs 1, 2. The cross-taper approach is the most commonly used strategy in clinical practice for switching between SSRIs 3, 4, 5.

Step-by-Step Approach:

Week 1:

  • Start sertraline 25-50 mg daily (lower dose if patient is sensitive to medication changes)
  • Continue current escitalopram dose
  • Monitor closely for anxiety, agitation, or serotonin syndrome symptoms in first 24-48 hours 6

Week 2:

  • Increase sertraline to therapeutic dose (50 mg for most indications, though 25 mg may be used initially for panic disorder) 2
  • Begin tapering escitalopram by 50% (e.g., from 10 mg to 5 mg)
  • Continue monitoring

Week 3-4:

  • Discontinue escitalopram completely
  • Maintain sertraline at therapeutic dose
  • Assess for discontinuation symptoms

Key Considerations

Discontinuation Syndrome Risk

Escitalopram has a shorter half-life than fluoxetine, making gradual tapering important 1. Abrupt cessation can cause discontinuation syndrome with symptoms including dizziness, sensory disturbances ("brain zaps"), anxiety, irritability, headache, and insomnia 1. While sertraline also carries discontinuation risk, it is generally better tolerated than paroxetine 6.

Serotonin Syndrome Monitoring

Although switching between two SSRIs carries theoretical risk of serotonin syndrome, this is very uncommon when transitioning between mechanistically similar SSRIs 7. However, monitor for: mental status changes (agitation, confusion), autonomic instability (tachycardia, diaphoresis, hyperthermia), neuromuscular symptoms (tremor, hyperreflexia), and GI symptoms (nausea, diarrhea) 1, 2.

Dosing Specifics

Sertraline therapeutic dosing:

  • Depression/OCD/PTSD/Social Anxiety: Start 50 mg, range 50-200 mg daily
  • Panic Disorder: Start 25 mg, increase to 50 mg after one week, range 50-200 mg daily 2

Escitalopram tapering:

  • If on 10 mg: reduce to 5 mg for 1 week, then discontinue
  • If on 20 mg: reduce to 10 mg for 1 week, then 5 mg for 1 week, then discontinue 1

Drug Interaction Differences

Escitalopram has the least effect on CYP450 enzymes among SSRIs, while sertraline has intermediate effects on CYP2D6 6. Review the patient's medication list for drugs metabolized by CYP2D6 (e.g., certain beta-blockers, antipsychotics, tamoxifen) as sertraline may cause modest interactions 6.

QTc Considerations

If QTc prolongation was a concern with escitalopram (which can prolong QT at doses >40 mg/day), sertraline may offer a modest advantage 8, though both require monitoring if other QT-prolonging medications are co-prescribed 6.

Common Pitfalls to Avoid

  • Do not abruptly stop escitalopram - this significantly increases discontinuation syndrome risk 1
  • Do not assume a washout period is needed - this is only required for MAOIs (14 days) 1, 2
  • Do not start sertraline at full therapeutic dose immediately in sensitive patients - begin with 25 mg to assess tolerability 2
  • Do not forget to reassess response at 6-8 weeks after completing the switch 9

Follow-Up Monitoring

Monitor within 1-2 weeks of initiating the switch for suicidal ideation (especially in patients <25 years), worsening depression, anxiety, agitation, or discontinuation symptoms 9, 1, 2. Continue monitoring at dose changes and assess full therapeutic response at 6-8 weeks 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.